Latest news and press releases about MetaVia Inc. (MTVA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
Price
| Price | $1.54 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.34 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · LSTA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of MTVA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks